scholarly journals Elastography, a sensitive tool for the evaluation of neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma

2014 ◽  
Vol 8 (4) ◽  
pp. 1652-1656 ◽  
Author(s):  
MENG XIE ◽  
XUYIN ZHANG ◽  
ZHAN JIA ◽  
YUNYUN REN ◽  
WENPING WANG
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Sensitive Tool

Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy

2015 ◽  
Vol 137 ◽  
pp. 43
Author(s):  
J.M. Stewart ◽  
A.A. Tone ◽  
M.Q. Bernardini ◽  
S.E. Ferguson ◽  
J. Dodge ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
High Grade ◽  
Serous Ovarian Carcinoma

Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma

2016 ◽  
Vol 141 ◽  
pp. 151-152
Author(s):  
R.C. Arend ◽  
Z.C. Dobbin ◽  
D.K. Crossman ◽  
B.K. Erickson ◽  
J.D. Boone ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Molecular Response ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Impact of Neoadjuvant Chemotherapy on Somatic Mutation Status in High-grade Serous Ovarian Carcinoma

2021 ◽  
Author(s):  
Zibi Marchocki ◽  
Alicia Tone ◽  
Carl Virtanen ◽  
Richard de Borja ◽  
Blaise Clarke ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Somatic Mutation ◽  
High Grade ◽  
Mutation Status ◽  
Synonymous Mutations ◽  
Platinum Sensitive ◽  
Serous Ovarian Carcinoma ◽  
Platinum Resistant ◽  
The Impact

Abstract BACKGROUND: Patients treated with neoadjuvant chemotherapy (NACT) for advanced high-grade serous ovarian carcinoma (HGSC) have a higher rate and shorter time to platinum-resistant recurrence compared to patients treated with primary cytoreductive surgery (PCS) and adjuvant chemotherapy. The purpose of this study is to determine the impact of NACT on somatic mutation status in platinum-sensitive and resistant HGSC. Patients with advanced HGSC who had a documented response to platinum-based NACT, a banked blood sample, and a banked tumor sample before and after NACT were identified. Whole exome and/or targeted deep sequencing was performed in matched normal and pre/post-NACT tumor samples from 3 platinum-resistant and 2 platinum-sensitive patients to identify somatic non-synonymous mutations at each time point.RESULTS: When comparing exonic non-synonymous mutations in pre-NACT and post-NACT samples from the same patient, an average of 41% (1-68%) of genes were mutated at both time points. There were no trends detected in the mutational burden following exposure to NACT in platinum-resistant vs. platinum-sensitive cases. The majority of mutated genes were unique to each case. We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases. Four mutated genes emerged exclusively in the platinum-resistant cases (ADGRV1, MUC17, MUC20, PAK2) following NACT.CONCLUSIONS: Patients with advanced HGSC present with significant intra-tumor heterogeneity. NACT significantly impacts the somatic mutation status irrespective of the time to recurrence. The mutated genes detected in chemo-naive pre-NACT tumor samples from either resistant or sensitive cases could potentially have a role in the prediction of chemotherapy response in patients scheduled to receive NACT; larger studies are required to further validate these genes.

scholarly journals Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

2018 ◽  
Vol 16 (5) ◽  
pp. 813-824 ◽  
Author(s):  
Rebecca C. Arend ◽  
Angelina I. Londoño ◽  
Allison M. Montgomery ◽  
Haller J. Smith ◽  
Zachary C. Dobbin ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Molecular Response ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Response To Neoadjuvant Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document